1. Home
  2. Medical News
  3. Sports Medicine
advertisement

Inject Trial: Achilles Injections Show No One-Year Benefit Over Sham

Achilles Injections Show No One Year Benefit Over Sham
11/20/2026

Key Takeaways

  • Among adults with midportion Achilles tendinopathy receiving shared exercise and advice, neither high-volume injection showed a clear one-year pain and disability advantage over sham.
  • Hydrocortisone showed a temporary six-week advantage over sham but fared worse than the steroid-free injection at 26 weeks.
  • The hydrocortisone formulation was less costly than sham with similar quality-adjusted life-years, despite no lasting clinical advantage.
  • No serious trial-related adverse events were recorded.
For adults with midportion Achilles tendinopathy, the question is whether a high-volume injection adds benefit to exercise, education, and activity-modification advice. Hydrocortisone could also change how long any symptom improvement lasts. Investigators compared injections with and without hydrocortisone against sham while all participants received the same supportive care.

In the single-center, community-based, participant- and assessor-masked trial of high-volume injections for midportion Achilles tendinopathy, adults received a low-volume bupivacaine sham injection or a high-volume saline and bupivacaine injection with or without hydrocortisone. All groups received exercise, education, and activity-modification advice. The primary clinical outcome was pain and disability on the Victorian Institute of Sport Assessment–Achilles (VISA-A) scale at one year. Investigators separately assessed societal cost per quality-adjusted life-year (QALY). The economic analysis used Australian-dollar willingness-to-pay thresholds, not measured savings or estimates of U.S. treatment costs.

At one year, the VISA-A difference for hydrocortisone-containing injection versus sham was −3.5 points (98% confidence interval [CI], −12.0 to 5.0). The steroid-free injection versus sham yielded a difference of +4.0 points (98% CI, −4.2 to 12.3). Both intervals crossed zero, so neither high-volume formulation had a clear advantage over sham. The head-to-head comparison between the two formulations was also unclear at the primary endpoint.

The hydrocortisone-containing injection showed a temporary VISA-A advantage over sham at six weeks. At 26 weeks, however, it trailed the steroid-free injection by −8.6 points (reported CI, −16.4 to −0.7). The separate societal-perspective analysis found lower costs with hydrocortisone-containing injection than with sham, despite similar QALYs, and reported a greater than 90% probability that the hydrocortisone-containing injection was cost-effective at willingness-to-pay thresholds of AUD $50,000 and $100,000 per QALY. This economic finding did not establish lasting improvement in Achilles symptoms. No serious trial-related adverse events were recorded.

Because all groups received exercise and advice, the trial assessed whether targeted high-volume injections added benefit over a low-volume bupivacaine sham injection delivered away from the target site—not whether injection is better than rehabilitation alone. The sham contained bupivacaine, so it was not an anesthetic-free comparison. Although the economic result favored the hydrocortisone formulation, it measured a different outcome from durable pain and disability relief. Its Australian-dollar thresholds do not establish whether the same economic finding would apply in a U.S. health system.

The investigators concluded that their clinical data did not support routine use of hydrocortisone-containing high-volume injection for midportion Achilles tendinopathy. Its early symptom benefit did not persist at the primary endpoint.

Clinician Questions

What did the sham injection contain in the Inject trial for midportion Achilles tendinopathy?

Adults assigned to sham received a low-volume injection of 2–3 mL of 0.5% bupivacaine hydrochloride; it was not an anesthetic-free injection.

What hydrocortisone dose and injection volume were used for midportion Achilles tendinopathy in the Inject trial?

The corticosteroid-containing high-volume injection comprised 50 mL of saline and bupivacaine, with 25 mg hydrocortisone in the first 10 mL. The other high-volume formulation omitted hydrocortisone.

This content is intended for healthcare professionals for educational purposes. The article and its image were developed with AI assistance and reviewed by members of the ReachMD team prior to publication. Please refer to the original source linked for the complete and most up-to-date information.

Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free